MN HF4349

Changes commissioner's authority from discretionary ("may") to mandatory ("shall") for providing separate hospital reimbursement for biological products used in cell or gene therapy to treat rare diseases

Removes the July 1, 2025 effective date and the requirement for federal approval of value-based arrangement documentation before implementation

Eliminates the requirement that drug manufacturers enter into value-based arrangements with the commissioner as a condition for separate reimbursement

Removes the methodology provision that tied reimbursement rates to outpatient drug pricing under section 256B.0625

Requires hospitals to be paid the actual acquisition cost for qualifying biological products provided in inpatient settings for rare disease treatment